Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement

Inflammatory Bowel Diseases

Volumn 15, Issue 10, 2009, Pages 1485-1491

  Gisbert, Javier P ^a   Bermejo, Fernando ^b   Pajares, Ramón ^c   Pérez Calle, Jose Lázaro ^d   Rodríguez, María ^a   Algaba, Alicia ^b   Mancenido, Noemí ^c   De La Morena, Felipe ^a   Carneros, Jose Antonio ^b   McNicholl, Adrián G ^a   González Lama, Yago ^a   Maté, José ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Anemia; Ferritin; Inflammatory bowel disease; Iron

Indexed keywords

ALPHA1 GLYCOPROTEIN; AZATHIOPRINE; C REACTIVE PROTEIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TRANSFERRIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FERROUS COMPOUNDS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349277116     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20925     Document Type: Article

References (55)

1. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-1523. (Pubitemid 44915199)
2. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-1553.
3. Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299-1307. (Pubitemid 351678000)
4. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190-1197. (Pubitemid 38961976)
5. Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:47-52. (Pubitemid 43032451)
6. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-130.
7. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:250-255. (Pubitemid 32776519)
8. Kawai M, Sumimoto S, Kasajima Y, Hamamoto T. A case of ulcerative colitis induced by oral ferrous sulfate. Acta Paediatr Jpn. 1992;34:476-478.
9. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003;38:543-548. (Pubitemid 36609862)
10. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-623. (Pubitemid 26076567)
11. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
12. WHO, UNICEF, UNU. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a joint WHO/UNICEF/UNU consultation. Geneva: World Health Organization; 1998.
13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;1041-1048.
14. de Dombal FT.Measuring and quantifying the status of patients with inflammatory bowel disease. In: de Dombal FT,Myren J,Bouchier IAD, et al, eds. Inflammatory bowel disease. Some international and data reflections.Oxford: Oxford University Press;1986:267-285.
15. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
16. Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities.] Schweiz Med Wochenschr. 1970;100:301-303.
17. Alcala MJ, Casellas F, Fontanet G, et al. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:383-391. (Pubitemid 39029181)
18. Lopez-Vivancos J, Casellas F, Badia X, et al. Validation of the Spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. Digestion. 1999;60:274-280. (Pubitemid 29221895)
19. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382-2387. (Pubitemid 32769199)
20. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(suppl 7A):44S-49S. (Pubitemid 38429899)
21. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 2001;96:2296-2298. (Pubitemid 32769186)
22. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6:142-150; discussion 151.
23. Hunt JM. Reversing productivity losses from iron deficiency: the economic case. J Nutr. 2002;132:794S-801S.
24. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-895. (Pubitemid 34839682)
25. de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003;9:316-320. (Pubitemid 37161751)
26. de Silva AD, Tsironi E, Feakins RM, et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22:1097-1105. (Pubitemid 41779517)
27. Allen LH. Iron supplements: scientific issues concerning efficacy and implications for research and programs. J Nutr. 2002;132:813S-819S.
28. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998;12:845-848.
29. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503-2509. (Pubitemid 43919683)
30. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-1065. (Pubitemid 41291355)
31. Erichsen K, Ulvik RJ, Grimstad T, et al. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:831-838. (Pubitemid 41564363)
32. Rockey DC. Treatment of iron deficiency. Gastroenterology. 2006;130:1367-1368.
33. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142-1147. (Pubitemid 41363767)
34. Zlotkin S, Arthur P, Antwi KY, et al. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics. 2001;108:613-616. (Pubitemid 32786588)
35. Makrides M, Crowther CA, Gibson RA, et al. Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. Am J Clin Nutr. 2003;78:145-153. (Pubitemid 39662686)
36. Reifen R, Matas Z, Zeidel L, et al. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci. 2000;45:394-397. (Pubitemid 30133904)
37. Carrier J, Aghdassi E, Platt I, et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001;15:1989-1999. (Pubitemid 34014356)
38. Aghdassi E, Carrier J, Cullen J, et al. Effect of iron supplementation on oxidative stress and intestinal inflammation in rats with acute colitis. Dig Dis Sci. 2001;46:1088-1094. (Pubitemid 32375042)
39. Carrier J, Aghdassi E, Cullen J, et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002;132:3146-3150.
40. Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, et al. Iron and inflammatory bowel disease. Aliment Pharmacol Ther. 2001;15:429-438.
41. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol. 2007;13:4798-4806. (Pubitemid 47496743)
42. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76:74-78.
43. Bartels U, Pedersen NS, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13:649-656. (Pubitemid 9003793)
44. Bodemar G, Kechagias S, Almer S, et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol. 2004;39:454-458. (Pubitemid 38626625)
45. Gasche C, Reinisch W, Lochs H, et al. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci. 1994;39:1930-1934.
46. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126:782-787.
47. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion. 1999;60:262-267. (Pubitemid 29221893)
48. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182-1192. (Pubitemid 351677967)
49. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34:286-290. (Pubitemid 34437521)
50. Schroder O, Schrott M, Blumenstein I, et al. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol. 2004;42:663-667. (Pubitemid 39166150)
51. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502-1504. (Pubitemid 46670290)
52. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-382. (Pubitemid 43159991)
53. Haas JD, Brownlie Tt. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131:676S-688S; discussion 688S-690S.
54. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am J Med. 2004;116(suppl 7A):1S-2S.
55. Leitgeb C, Pecherstorfer M, Fritz E, et al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994;73:2535-2542. (Pubitemid 24155530)